Compare Peptides
Select any two compounds for a side-by-side comparison of mechanism, uses, risks, and FDA regulatory status.
Popular comparisons
GHK-Cu
Copper Peptide, Glycyl-L-histidyl-L-lysine:copper(II)
A naturally occurring copper-binding tripeptide found in human plasma, saliva, and urine. Levels decline significantly with age. Widely used in both injectable and topical forms for anti-aging.
A synthetic tetrapeptide (Ala-Glu-Asp-Gly) originally developed by the St. Petersburg Institute of Bioregulation and Gerontology in Russia. Studied for telomere lengthening, melatonin regulation, and anti-aging properties.
Activates wound healing genes, promotes collagen and elastin synthesis, stimulates blood vessel growth, and has anti-inflammatory and antioxidant properties. The copper ion is essential for many enzymatic processes in tissue remodeling.
Stimulates the pineal gland to increase melatonin production. Activates telomerase, an enzyme that maintains telomere length, potentially slowing cellular aging. Also reported to normalize circadian rhythms and modulate neuroendocrine function.
- Skin rejuvenation and anti-aging
- Wound healing
- Hair growth stimulation
- Collagen production
- Reducing inflammation
- Anti-aging and longevity protocols
- Improved sleep quality
- Telomere length maintenance
- Cancer prevention (preliminary research)
- Circadian rhythm regulation
- Generally well-tolerated topically
- Injectable form has less safety data
- Potential copper toxicity at high doses
- Skin irritation possible with topical use
- Very limited human clinical data
- Most research from Russian institutions with limited peer review
- Long-term safety unknown
- Injection site reactions
- Theoretical concerns around telomerase activation and oncogenesis
GHK-Cu has a notably complex status after the April 15, 2026 FDA announcement. Injectable GHK-Cu is being removed from Category 2 (significant safety risks), while non-injectable GHK-Cu is simultaneously being removed from Category 1 (active evaluation). Both forms are scheduled for a unified PCAC review before February 2027. Topical cosmetic use is unaffected. Injectable use is now in regulatory gray zone — compounding pharmacies should not assume authorization until PCAC acts.
PCAC: By February 2027
Removed from FDA 503A Category 2 effective April 22, 2026. Scheduled for PCAC review on July 24, 2026. Most research originates from Russian institutions; limited independent Western replication. Compounding not yet authorized — status is in regulatory gray zone pending PCAC recommendation.
PCAC: July 24, 2026
This comparison is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy.